Drug
BI 425809 clinical trials
Also written Iclepertin and BI 425809.
- studies test it
- 28
- open now
- 0
- in phase 3
- 4
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
28 studies that test it; most in 2015 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 5 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 21
- Phase 2
- 3
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 28 · Other 0
Often tested with
Tested in the same studies.
Midazolam (2) · Itraconazole (1) · Fluconazole (1) · Warfarin (1) · Omeprazole (1) · Digoxin (1) · Bosentan (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses BI 425809 is read from its arms, and is right about nine times in ten.
Testing it · 28
- Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02342717Written as BI 425809
- Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809CompletedPhase 1Boehringer IngelheimNCT02068690Written as BI 425809 PfOS
- Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)CompletedPhase 1Boehringer IngelheimNCT02337283Written as BI 425809
- A Study in Healthy Women to Test Whether BI 425809 Influences the Amount of a Contraceptive in the BloodCompletedPhase 1Boehringer IngelheimNCT05613777Written as Iclepertin
- A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT05076409Written as BI 425809
- Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809CompletedPhase 1Boehringer IngelheimNCT02362516Written as BI 425809
- A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT03817476Written as iCF1(T1) 25 milligram BI 425809
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver ProblemsCompletedPhase 1Boehringer IngelheimNCT05731895Written as Iclepertin
- A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without FoodCompletedPhase 1Boehringer IngelheimNCT05347004Written as BI 425809
- Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and DigoxinCompletedPhase 1Boehringer IngelheimNCT02783040Written as BI 425809
- A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX StudyTerminatedPhase 3Boehringer IngelheimNCT05211947Written as Iclepertin
- A Study in Healthy Men to Test Whether Bosentan Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT05723874Written as BI 425809
- A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the BloodCompletedPhase 1Boehringer IngelheimNCT05258110Written as iclepertin (BI 425809)
- A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney ProblemsCompletedPhase 1Boehringer IngelheimNCT05718843Written as BI 425809
- Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male SubjectsCompletedPhase 1Boehringer IngelheimNCT02383888Written as BI 425809
- A Study in Healthy Men to Test Whether Rifampicin Influences the Amount of BI 425809 in the BloodCompletedPhase 1Boehringer IngelheimNCT03082183Written as BI 425809
- A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the BodyCompletedPhase 1Boehringer IngelheimNCT03654170Written as BI 425809 mixed with [C-14] BI425809
- A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a TabletCompletedPhase 1Boehringer IngelheimNCT03783000Written as BI 425809
- CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With SchizophreniaCompletedPhase 3Boehringer IngelheimNCT04860830Written as Iclepertin
- Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)CompletedPhase 3Boehringer IngelheimNCT04846881Written as Iclepertin
Codes
What other systems call BI 425809 · ClinicalTrials.gg INT001170
- MeSH (NLM) C000634404BI 425809One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000634404 | BI 425809 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.